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Biological markers, or ‘biomarkers,’ have 
application in diagnostic, prognostic and 
therapeutic investigations, with an ever-
increasing catalog of endogenous biologi-
cal entities such as proteins/peptides, lipids 
and metabolites being used in clinical set-
tings. Uses of biomarkers include diagnostic 
rule in/out tests (e.g., high-sensitive tropo-
nin for acute myocardial infarction [1]), risk 
stratification/prediction of patient outcome 
(e.g., natriuretic peptides in cardiovascu-
lar diseases [2]) and monitoring of response 
to administered medicines (e.g., metabolic 
signatures of pharmacological interven-
tions [3]). The use of biomarkers, and sub-
sequently their success in improving person-
alized clinical information, relies on the 
collection, processing and analysis of bio-
logical samples which should be done to an 
established protocol. MS, an analytical tech-
nology capable of measurements with high 
levels of reproducibility, precision and accu-
racy, has received recent interest in clinical 
research for its potential to extend current 
capabilities in biomarker discovery, devel-
opment and validation [4]. Technological 
advances are not without pitfalls, with deli-
cate balancing of cost-to-benefit and cross-
site reproducibility required to justify more 
widespread implementation. This editorial 
looks to highlight the major advantages of 
MS in the clinical laboratory, explain the 
major hurdles in place and provide an insight 
into the potential applications for clinical 
biomarker analysis.
MS is capable of measuring a wide 
range of biomarkers from small molecules 
(<50 Da) to large macromolecular struc-
tures (>10,000 Da) across large dynamic 
ranges, suitably placing its use for clinical 
biomarker analysis. This analysis is achieved 
through the application of varied MS tech-
niques that can be modified and tuned to 
target biomarker(s) of interest. In addition, 
analysis of multiple sample matrices is possi-
ble, with MS techniques extending from the 
traditional blood (plasma/serum) and urine 
measure ments to include volatile and nonvol-
atile molecules in saliva [5,6], sweat and skin 
secretions [7], exhaled breath gases [8] and 
tissue slices [9]. Hyphenated MS techniques, 
such as LC– or GC–MS, provide increased 
utility through the separation of many 
hundreds of biological molecules, thereby 
reducing analytical complexity. This separa-
tion staggers the entry of molecules into the 
mass spectrometer, reducing the potential 
number of molecules present per analytical 
scan. Importantly, conditions employed for 
chromatographic separations can be manipu-
lated to optimize biomarker sensitivity and 
minimize analytical run times, therefore 
improving sample throughput. Further, the 
inclusion of stable isotopically labeled inter-
nal standards corrects for inter-run varia-
tion, maximizing reproducibility and accu-
racy of biomarker quantitation. Extending 
from chromatographic-based systems, direct 
analysis methods such as MALDI–MS 
can provide additive clinical information. 
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For example, the measurement of molecules present 
on the surface of a tissue biopsy can delineate tissue 
characteristics to discriminate between cancerous and 
 noncancerous cells [9].
The US FDA has approved several MS-based meth-
ods as in vitro diagnostic devices including neonatal 
screening of inborn errors of metabolism, identifica-
tion of microbial species and measurements of thera-
peutic drugs in the circulation [10]. Barriers that have 
slowed the progression of these methods in a clinical 
setting have been associated with the ability to control 
sample collection, preparation and analytical interpre-
tation across instrument vendors and models, opera-
tors and hospital sites [10]. These additive sources of 
variation necessitate extensive testing to be performed 
to ensure that the reproducibility of an assay is robust 
for common use and that varying results do not affect 
the validity of the result, and therefore its effectiveness 
in clinical decision making. Regulatory issues further 
add to the complexity of clinical adoption of MS-
based assays, and are an ongoing matter that is being 
addressed by involved parties (e.g., industry, healthcare 
bodies). The constant technological evolution of MS 
provides cumulative benefits from an analytical view-
point (e.g., improvements in sensitivity and selectivity) 
but adoption may be limited by regulatory constraints.
Further extension of these MS-based clinical tests 
for more widespread use have also been hindered 
through the demands required to install, run and 
maintain the complex analytical systems. High initial 
costs for equipment purchase and the facilities required 
to house and operate the instruments places an enor-
mous financial burden on any hospital or healthcare 
system that wishes to implement MS into its clinical 
assessments. Although costs remain high, more afford-
able mass spectrometers have been introduced into the 
commercial market, albeit often providing reduced 
functionality to their more expensive counterparts. A 
major stumbling block for hospital-based MS is the 
requirement for a constant flow of inert gas(es) and 
the space required to place both the instrumentation 
and the background equipment required for operation 
(e.g., vacuum pumps, air compressors and gas genera-
tors). Many of the modern mass spectrometers avail-
able exhibit a reduced footprint and can be combined 
with purpose-built benches that contain the necessary 
background equipment within a sound-insulated base. 
Although this arrangement is not preferred, it allows 
MS use in laboratories, which may not have otherwise 
suitable facilities. Furthermore, the development of 
more user-friendly software packages has simplified 
the training for novice users and subsequently reduced 
the reliance on highly experienced personnel for rou-
tine analytical operation. However, this cannot negate 
the specific expertise and proficiency required for MS 
method development and validation and therefore 
laboratories must be supported by technical experts, 
increasing operation costs.
Clinical integration of MS is being enhanced 
through the development of instruments intended 
for use at the point-of-care (POC). POC devices are 
vital for rapid identification and characterization of 
biomarkers, with the modification and miniaturiza-
tion of MS-based systems driving a real potential for 
the implementation of MS at the bedside. Leading this 
innovation is the development of the iKnife to cauter-
ize tissue during surgery, directing fumes of vaporized 
molecules into a mass spectrometer positioned within 
the operating theater, allowing in vivo identification of 
healthy and diseased tissue [11,12]. Although the iKnife 
is present within the operating theater, it requires the 
use of an advanced mass spectrometer that cannot be 
relocated between surgeries. Recent developments in 
miniaturization of mass spectrometers offer the poten-
tial for sampling in the field (e.g., in ambulances) and 
at the bedside, expanding the use of biomarkers at the 
POC. Researchers at Purdue University have pioneered 
the development of the ‘mini mass spec’, producing an 
instrument that can be carried by a handle and used 
in any location [13]. Additionally, the development of 
paperspray MS has allowed direct analysis of tissue 
biopsies by applying a solvent spray and high voltage 
to a triangular-shaped porous paper at the entrance of 
the mass spectrometer [14]. Further clinical develop-
ments have been made in exhaled breath gas analysis, 
with a compact quadrupole mass spectrometer capable 
of real-time measurement of exhaled volatiles at the 
bedside [8], currently being employed into the multi-
center East Midlands Breathomics Pathology Node 
research program [15]. These advancements provide the 
potential to rapidly screen biological samples to make 
near-instant clinical judgements within a hospital set-
ting, with added potential to be deployed into general 
 practitioner surgeries for routine health assessments.
With the growing reliance on personalized medi-
cine, MS has an innate ability to improve clinical deci-
sion making through the measurements of biomarkers 
that may not be detectable by alternative methods. For 
example, current immunoassays to measure BNP for 
cardiovascular disease suffer from a lack of specific-
ity to detect the intact BNP molecule, also measuring 
its truncated forms that are co-existent in the circu-
lation [16]. To this end, we recently reported that a 
selection of these truncated forms was useful in risk 
stratification of acute heart failure patients [17], and 
that understanding the distribution of these differ-
ent forms requires the use of MS. Furthermore, the 
impact of the gut microbiome has been implicated in 
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disease development. Notably, TMAO, a gut-derived 
metabolite, was initially characterized using MS-based 
nontargeted metabolomics [18] and has since shown to 
be an independent prognostic predictor in multiple 
cardiovascular disease states [19,20]. Although TMAO 
is not currently measured in clinic, the necessary steps 
to incorporate it into routine clinical analysis are being 
taken. Further MS-based experiments incorporating 
global ‘omics based approaches, such as metabolo-
mics and proteomics, are likely to continue to uncover 
novel disease-specific biomarkers that show associative 
or direct mechanistic relationships with the onset of 
 conditions and/or future risk of adverse events.
To conclude, the major bottlenecks for implemen-
tation of MS-based clinical assays are its costs and, 
perhaps more importantly, the need for methods to 
be approved by healthcare regulatory authorities who 
may be hesitant to support MS-based methods without 
extensive testing across institutions. To overcome this, 
further work toward simplified and approved analyti-
cal kits, as well as the ability to automate preparation 
and analysis using methods that can be shared glob-
ally to provide cross-validation of care across health-
care systems is required. As MS becomes gradually 
more commonplace in the clinical laboratory, the true 
benefits of its use will become rapidly apparent and we 
expect to see many more clinically applied MS meth-
ods published in both scientific literature and on regu-
latory approval lists. It is not said that MS will replace 
current low-cost and reliable clinical tests, but as bio-
marker testing evolves MS has the ability to broaden 
the inventory of disease-specific molecules and place 
itself within a clear niche in which to excel.
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